Mayo Clinic

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

Lucem Health is a company focused on developing a remote diagnostics platform that integrates remote patient telemetry and biosensing devices with artificial intelligence algorithms. The platform is designed to enhance data ingestion, orchestration, and connectivity, which allows clinicians to deliver more effective continuous care. It supports the development and deployment of clinical AI models that facilitate point-of-care solutions, enabling healthcare providers to gain valuable insights directly from clinical data. By streamlining the execution of AI models and integrating these insights into clinical workflows, Lucem Health empowers both clinicians and consumers to improve health management and enhance overall well-being.

Mediwhale is a health diagnostics company that focuses on leveraging artificial intelligence to enhance the prevention of cardiovascular and kidney diseases. It operates a unique AI screening platform that assesses metabolic risks and diagnoses eye diseases through non-invasive retinal scans. The platform comprises several components, including RetiCVD for cardiovascular disease risk assessment, which utilizes coronary artery calcium scores to predict risks based on established guidelines. RetiCKD offers a chronic kidney disease risk assessment with improved predictive capabilities compared to traditional methods. Additionally, RetiEYE identifies common age-related eye diseases like diabetic retinopathy and glaucoma at their referable stages. Mediwhale's retinal-based systemic biomarkers have been clinically validated and are recognized in the medical community, supported by publications in reputable journals. Through its innovative approach, Mediwhale aims to establish a sustainable healthcare model that emphasizes early detection and intervention.

Healium is a mental fitness tool that offers a drugless approach to managing anxiety, sleep, addiction, and burnout. The company utilizes patented technology that connects to biometric data from consumer wearables, such as smartwatches and EEG headbands, allowing users to monitor their brainwaves and heart rate. This information is used to create a reactive, immersive media experience that adapts to the user's bio-data. Healium's unique platform has been validated by eight peer-reviewed studies, demonstrating its effectiveness in reducing anxiety and improving mood within minutes. By leveraging existing sensors and devices, Healium provides a controlled virtual and augmented reality environment for users seeking to enhance their mental well-being.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Genomadix is a company that specializes in developing molecular testing technologies aimed at addressing infectious diseases, precision medicine, and water safety. It has created a diagnostic platform that incorporates a portable molecular analyzer utilizing polymerase chain reaction (PCR) technology. This innovative approach allows for quick and accurate test results to be generated outside of traditional healthcare settings. By facilitating rapid diagnostics, Genomadix enables healthcare professionals and patients to make informed, real-time healthcare decisions, thereby improving the overall quality of care and response to various health challenges.

Karkinos Healthcare is technology-driven oncology focussed managed health care platform for the early detection and diagnosis of common cancers.

Medically Home Group, Inc. is a Boston-based company that specializes in delivering virtual hospital services, enabling patients to receive medical care in the comfort of their homes. Founded in 2016, the company offers a comprehensive program that addresses various medical conditions, including heart failure, pneumonia, chronic obstructive pulmonary disease (COPD), and urinary tract infections, among others. By utilizing a technology-enabled platform, Medically Home connects patients with caregivers and facilitates monitoring and communication for individuals with high-acuity illnesses. This approach allows patients and their families to access centralized, on-demand acute medical care management, effectively shifting the focus of healthcare from traditional hospital settings to home-based care.

Tympany is a platform for performing minimally invasive ear surgeries, reducing unnecessary mastoidectomys and improving outcomes.

JOGO Health is a virtual care company that specializes in digital therapeutics aimed at treating pain, neuromuscular conditions, and pelvic floor disorders. The company utilizes a combination of an AI-driven mobile app and wearable wireless sensors to deliver clinically proven interventions. These technologies offer treatment protocols and interactive games designed to enhance muscle relaxation, movement coordination, and neuromuscular reeducation. By leveraging the brain's neuroplasticity, JOGO Health enables healthcare providers to improve patient adherence to rehabilitation, ultimately leading to better health outcomes for individuals suffering from conditions such as stroke, chronic pain, and pelvic health issues.

Medically Home Group, Inc. is a Boston-based company that specializes in delivering virtual hospital services, enabling patients to receive medical care in the comfort of their homes. Founded in 2016, the company offers a comprehensive program that addresses various medical conditions, including heart failure, pneumonia, chronic obstructive pulmonary disease (COPD), and urinary tract infections, among others. By utilizing a technology-enabled platform, Medically Home connects patients with caregivers and facilitates monitoring and communication for individuals with high-acuity illnesses. This approach allows patients and their families to access centralized, on-demand acute medical care management, effectively shifting the focus of healthcare from traditional hospital settings to home-based care.

Anumana develops advanced AI algorithms that analyze electrocardiogram (ECG) data to facilitate early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing healthcare professionals with tools to identify potential heart issues more effectively. Anumana's platform supports not only diagnostics but also aims to improve patient outcomes across the entire spectrum of cardiovascular care, including perioperative and acute settings. By employing machine learning techniques, Anumana seeks to refine screening processes, enabling clinicians to detect heart diseases and intervene promptly. This approach enhances healthcare delivery and promotes better management of cardiovascular health.

Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.

Securisyn Medical, LLC is a medical technology company based in Highlands Ranch, Colorado, that specializes in the manufacture and supply of oxygen delivery systems for mechanically ventilated patients. Founded in 2011, the company focuses on enhancing patient safety and preventing unplanned extubation, which can lead to serious complications. Its innovative airway stabilization system features a ribbed endotracheal tube and an interlocking stabilizer, providing additional security for the airway and protecting critical components. Securisyn Medical serves healthcare providers and medical facilities across the United States, striving to reduce preventable deaths related to airway management while also decreasing overall healthcare costs. The company's commitment to ethical and sustainable practices underpins its mission to improve outcomes for patients, their families, and practitioners.

Progentec Diagnostics, Inc. is focused on developing advanced diagnostic tests aimed at improving the management of systemic lupus erythematosus (SLE). The company's flagship platform, aiSLE DX, offers tools such as a flare prediction score, which proactively measures disease activity, and an early diagnosis test for lupus. Established in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and experts globally to leverage innovations in diagnostics. The company is dedicated to addressing significant unmet needs in healthcare by enhancing disease management through improved diagnostic capabilities, ultimately aiming to facilitate early detection and reduce disease incidence.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Ambient Clinical Analytics, Inc. develops healthcare data assimilation and decision support tools aimed at enhancing patient care in intensive care units, operating rooms, and emergency departments. The company's flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver crucial patient information on a single-screen dashboard, facilitating real-time clinical decision-making. Additionally, Ambient offers the Mayo Clinic YES Board, which enhances patient flow by providing real-time situational awareness. The company also specializes in syndromic surveillance solutions, including Sepsis DART, which aids in the detection and confirmation of sepsis, and the Ventilator-Induced Lung Injury Sniffer, designed for ventilator monitoring. Furthermore, Ambient provides the Synthesis Platform, which serves as an integration tool for AWARE and the Mayo Clinic solutions. Founded in 2013 and headquartered in Rochester, Minnesota, Ambient Clinical Analytics focuses on reducing healthcare costs and improving patient outcomes through its innovative tools and technology.

Geneticure Inc. is a pharmacogenetic testing company based in Eden Prairie, Minnesota, founded in 2012. The company specializes in developing tests that enable personalized medicine, particularly for patients with hypertension. Geneticure has created a patented cheek-swab test that predicts individual responses to high blood pressure medications and therapies. The testing process involves DNA extraction and genotyping, and the results are directly provided to healthcare providers alongside a summary of the genetic findings and a decision tree for treatment optimization. These tools are designed to assist clinicians in determining the most effective treatment methods for managing high blood pressure, ultimately allowing patients to utilize painless and affordable at-home testing to reach their blood pressure goals. Geneticure is backed by the Mayo Clinic, emphasizing its commitment to clinical evidence and personalized patient care.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Progentec Diagnostics, Inc. is focused on developing advanced diagnostic tests aimed at improving the management of systemic lupus erythematosus (SLE). The company's flagship platform, aiSLE DX, offers tools such as a flare prediction score, which proactively measures disease activity, and an early diagnosis test for lupus. Established in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and experts globally to leverage innovations in diagnostics. The company is dedicated to addressing significant unmet needs in healthcare by enhancing disease management through improved diagnostic capabilities, ultimately aiming to facilitate early detection and reduce disease incidence.

DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.

AliveCor, Inc. develops advanced mobile electrocardiogram (ECG) technology that transforms smartphones into clinical-quality heart monitoring devices. The company offers KardiaMobile, a personal ECG device for the instant detection of common heart arrhythmias, along with KardiaMobile 6L, which provides detailed 6-lead ECGs that patients can share with their healthcare providers. Additionally, AliveCor has introduced KardiaCare, a digital health subscription service that allows users to manage their heart health conveniently at home. Founded in 2010 and headquartered in Mountain View, California, AliveCor is recognized for its innovative use of machine learning techniques to enhance proactive heart care and improve stroke prevention through early atrial fibrillation detection.

Lifecode, Inc. is a molecular diagnostics company specializing in next-generation sequencing (NGS) technology. Based in Foster City, California, Lifecode develops a range of NGS-based cancer assays, including a pan cancer somatic panel designed for use in metastatic, rare, and refractory cancers, as well as in patients seeking clinical trials. The company aims to assist physicians in making informed treatment decisions by providing clinical information derived from extensive genomic and therapeutic data. Lifecode combines expertise in data science, software engineering, and molecular biology to effectively analyze and interpret complex genetic information. Its flagship product, the Lifecode Pan Cancer Somatic Panel, is currently offered to a select group of physicians in the United States. Lifecode was formerly known as Silicon Valley Biosystems and became a subsidiary of MedGenome Labs Private Ltd. in 2016.

Ambra Health is a medical data and image management company that provides a cloud-based platform designed to enhance the accessibility and management of medical images. The platform is intuitive, flexible, and scalable, enabling healthcare providers, including prominent health systems and clinical research organizations, to improve their imaging workflows and collaborative care. By offering secure and straightforward access to medical images, Ambra Health facilitates better internal adoption and collaboration among healthcare professionals. This capability allows organizations to significantly enhance their operational efficiency and patient care outcomes by making medical images and data accessible from anywhere.

Better is your Personal Health Assistant. Developed in partnership with Mayo Clinic and Social+Capital Partnership, our service provides free tools and premium access to a team of real Personal Health Assistants so you can spend less time managing the logistics and more time improving your health.

Ambient Clinical Analytics, Inc. develops healthcare data assimilation and decision support tools aimed at enhancing patient care in intensive care units, operating rooms, and emergency departments. The company's flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver crucial patient information on a single-screen dashboard, facilitating real-time clinical decision-making. Additionally, Ambient offers the Mayo Clinic YES Board, which enhances patient flow by providing real-time situational awareness. The company also specializes in syndromic surveillance solutions, including Sepsis DART, which aids in the detection and confirmation of sepsis, and the Ventilator-Induced Lung Injury Sniffer, designed for ventilator monitoring. Furthermore, Ambient provides the Synthesis Platform, which serves as an integration tool for AWARE and the Mayo Clinic solutions. Founded in 2013 and headquartered in Rochester, Minnesota, Ambient Clinical Analytics focuses on reducing healthcare costs and improving patient outcomes through its innovative tools and technology.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.